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Abstract
Background: Adhesion of platelets onto immobilized fibrinogen is of importance in initiation and
development of thrombosis. According to a recent increase in evidence of a multiple biological
property of antithrombin, we evaluated the influence of antithrombin on platelet adhesion onto
immobilized fibrinogen using an in-vitro flow system.
Methods: Platelets in anticoagulated whole blood (29 healthy blood donors) were labelled with
fluorescence dye and perfused through a rectangular flow chamber (shear rates of 13 s-1 to 1500
s-1). Platelet adhesion onto fibrinogen-coated slips was assessed using a fluorescence laser-scan
microscope and compared to the plasma antithrombin activity. Additionally the effect of
supraphysiological AT supplementation on platelets adhesion rate was evaluated.
Results: Within a first minute of perfusion, an inverse correlation between platelet adhesion and
plasma antithrombin were observed at 13 s-1 and 50 s-1 (r = -0.48 and r = -0.7, p < 0.05,
respectively). Significant differences in platelet adhesion related to low (92 ± 3.3%) and high (117 ±
4.1%) antithrombin activity (1786 ± 516 U vs. 823 ± 331 U, p < 0.05) at low flow rate (13 s-1, within
first minute) have been found. An in-vitro supplementation of whole blood with antithrombin
increased the antithrombin activity up to 280% and platelet adhesion rate reached about 65%
related to the adhesion rate in a non-supplemented blood (1.25 ± 0.17 vs. 1.95 ± 0.4 p = 0.008,
respectively).
Conclusion: It appears that antithrombin in a low flow system suppresses platelet adhesion onto
immobilized fibrinogen independently from its antithrombin activity. A supraphysiological
substitution of blood with antithrombin significantly reduces platelet adhesion rate. This inhibitory
effect might be of clinical relevance.
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Background
The scope of the problem of arterial and venous thrombo-
sis is staggering since at least 5 million adults in the
United States alone suffer from related symptoms. About
50% of the annual non-accidental deaths in the United
States are caused by thrombi predominantly composed of
platelets in the coronary or cerebral arteries.
Antithrombin (AT), in the past also referred as anti-
thrombin III, is a potent inhibitor of the coagulation cas-
cade [1]. Although the name, antithrombin, implies that
it works only on thrombin, it actually serves to inhibit vir-
tually all of the coagulation enzymes to at least some
extent. The primary enzymes it inhibits are factor Xa, fac-
tor IXa and thrombin (factor IIa). AT have also inhibitory
actions on the factor XIIa, factor XIa, complex of factor
VIIa and tissue factor. AT ability to limit coagulation
through the multiple interactions makes it one of the pri-
mary natural anticoagulant proteins [1,2].
AT is a 58 kd single-chain α2-glycoprotein with plasma
concentration of approximately 150 μg/mL. AT is com-
posed of 432 amino acids to which four oligosaccharide
chains are attached [3]. The inhibition of thrombin is due
to forming a 1:1 stoichiometric complex between the two
components via one reactive site (arginine)-active centre
(serine) interaction. This relatively slow interaction is dra-
matically accelerated in the presence of heparin. Through
the binding of heparin on the AT and consecutive change
of AT configuration capability to neutralise clotting
enzymes increases above the 1000 folds [1,4]. This inter-
action is also the basis for the use of heparin and low-
molecular-weight heparin as medications as anticoagu-
lants [4,5].
Once formed, the equimolar thrombin-antithrombin
(TAT) complex is removed in the liver with one half-life of
less than 5 minutes (half-life of native AT is about 60
hours) [1]. AT have multiple biological properties, which
are in last few years in focus of interest of many research-
ers [5-12].
A rapid AT consumption was observed in different clinical
entities [1,11]. Since decreased AT plasma concentration
correlated with increased mortality in related clinical
events, the concept of exogenous AT substitution has been
established [11]. Conducted studies showed that a benefi-
cial effect of AT in some clinical events may be due to both
its anticoagulant activity and the other unknown activity
[12]. In some extent clinical improvements were associ-
ated with significant modulation of interleukin-6 plasma
levels and down regulation of intercellular adhesion mol-
ecule-1 (ICAM-1), as well as E-selectin [12,13]. It has been
recently shown that AT causes a reduction of ischaemia-
reperfusion induced damage of renal tissue [14]. This
effect seems not be caused solely by inhibition of
thrombin generation because selective inhibition of
thrombin did not prove similar effect [8,14]. Hoffmann et
al. [15] reported that AT reduces the endotoxin-induced
leukocyte adherence onto vessel wall and improves capil-
lary perfusion. Inhibitory effects of AT on leukocyte and
platelet recruitment to the post ischaemic retina and con-
secutive protective property against ischaemia/reper-
fusion injury were also observed in vivo rat model
[10,16]. However, up to day there is no information about
the effects of AT on the platelet adhesion under various
flow conditions. In this study we evaluated role of AT on
the platelet adhesion onto immobilized fibrinogen under
different shear stress conditions.
Methods and subjects
Subjects
Twenty-nine healthy blood donors from our blood bank
were enrolled in this study. Mean age was 44 ± 12 years,
21 were men and eight were women. None of the donors
had taken any medication in the preceding 14 days.
Women on hormone replacement therapy and hormonal
contraception, smokers, obese persons, persons with pos-
itive familiar anamnesis related to the arterial or venous
vessel disease were excluded. Global coagulation tests, fac-
tors of coagulation and standard biochemical parameters
were in the normal range according to the international
standards. This study was performed according to the Hel-
sinki declaration and was approved by the local ethical
committee.
Blood preparation
Venous blood obtained from the cubital vein was imme-
diately anticoagulated with PPACK in final concentration
of 40 μM. During incubation period (60 min at 37°C)
platelets were labelled with fluorescence dye Mepacrine
(quinacrine dihydrochloride final concentration of 10
μM; Sigma Chemical), which was immediately accumu-
lated by delta granules of platelets [17]. The blood was
perfused through rectangular flow chamber within 2
hours of withdrawal.
Effect of supraphysiological AT substitution onto platelet
adhesion was tested in blood obtained from eight sub-
jects. The collected blood was aliquoted and one aliquot
was additionally incubated with AT (30 min, 2.8 IU/ml of
blood, Kybernin 500, Aventis, Marburg, Germany) prior
to perfusion through the flow chamber. In control experi-
ments the same volume of 0.9% NaCl was added to blood
prior to perfusion. Blood obtained from eight subjects
were anticoagulated with PPACK and blood obtained
from four donors were anticoagulated with heparin (17/
IU/ml, Liquemin N, Hoffmann-La Roche AG, Grenzach-
Wyhlen, Germany).Thrombosis Journal 2006, 4:19 http://www.thrombosisjournal.com/content/4/1/19
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Preparation of fibrinogen coated cover slips
Glass cover slips (24 × 50 mm) coated with 50 μl of fibrin-
ogen solution (2,5 mg/ml, Sigma-Aldrich) that a sharp
interface of the adhesion molecule was formed 10 mm
away from the smaller edge of the cover slip [17]. The
cover slip was placed in a humid environment (60 min at
37°C) to allow the protein to adhere to the glass surface.
Coated cover slips were rinsed with 10 ml of 50 mmol/l
phosphate buffered saline (pH 7.35, Serag-Wiessner, Ger-
many) to remove the non-adherent fibrinogen and placed
in the flow chamber. Fibrinogen density on the glass sur-
faces was calculated to be 0.13 μg/mm2. For the control
experiments cover slips were coated with bovine serum
albumin in final concentration of 5 μg/mm2. A specificity
of binding of platelets to immobilized fibrinogen was
tested in experiments with blood preincubated with
Abciximab (c7E3, Centocor, Inc; 4 μg/mL, 10 min). c7E3
Fab is a chimerical human/mouse Fab fragment derived
from the murine monoclonal 7E3 antibody that binds
selectively to the GP IIb-IIIa.
Flow chamber and laser-scan microscopy
The assessment of platelet adhesion rate onto fibrinogen
coated glass cover slips was conducted in the rectangular
flow chamber [17,18] under shear rate of 13 s-1 50 s-1 and
1500 s-1. Fibrinogen-coated glass cover slip with a flow
path height of 50 μm, determined by silicon gasket,
formed one side of flow chamber. Assembled flow cham-
ber was filled by a phosphate buffered saline (pH 7.35).
According to Newtonian fluid axiom, a shear stress is con-
stant and dependent upon the flow rate (Perfusor, B.
Braun, Meslingen, Germany). A shear rate of 13 s-1 and 50
s-1 mimics a venous wall shear rate and shear rate of 1500
s-1 represents a shear rate of larger arteries as well as a high
shear rate by moderate arterial stenosis [19]. One recent
study indicated that a platelet function and a mechanism
of adhesion and thrombus formation under these shear
rates differ from each other [17,20]. A laser-scan micro-
scope (Axiovert 100M, Carl-Zeiss, Jena, Germany)
allowed real-time visualisation of labelled platelets during
perfusion through the chamber. To assess time-course of
platelet adhesion a series of images (five images per series,
0,7 s pro image) were made at 15 sec, 1 and 5 minutes.
Image analysis was performed using the ImageJ software
(version 1.26t, NIH, USA). This program allows evalua-
tion of platelet-surface interaction, consecutive aggrega-
tion and evaluation of thrombus generation within the
defined area of each image. A single frame image corre-
sponded to the area of 980 × 980 μm. The blood was per-
fused over fibrinogen-coated cover slips as described
above. The number of stable, attached platelets on the sur-
face was calculated as number of platelets, which remain
their initial adhering position in the first and second
image (time frame of 0.7 sec). Platelets were considered to
move on the surface when exhibiting a spatial displace-
ment greater than one platelet diameter. To estimate
motion, a series of 5 images (time frame 0.7 sec) at one
time point were made. Using ImageJ software images were
binarised and a threshold was applied to distinguish
platelet from background. The first two consecutive
frames in a series were superimposed using the logical
AND function and the resulting image represented only
the overlapping areas of single platelet at two different
times.
Calculations and statistics
Data in this study are given as mean values ± SD. The
absolute fluorescence was expressed as arbitrary units
(pixel units, AU) and represents sum of fluorescence of
each thrombus or individual adherent platelet in one
defined area. Only platelets, which show stable adherence
during one image series, were taken into calculation. The
platelet adhesion was calculated using a logic function of
the applied software (ImageJ) and represented a stable
platelet adhesion between the first and second image. A
dynamic of platelets adhesion in function of time was
defined as increase (or decrease) of the absolute fluores-
cence between the first and fifth minute of perfusion.
Differences between experimental groups were tested
using Student's t-test (two-sided). Regression analyses
were based on individual measurements using Spear-
man's rank correlation coefficient. Statistical analyses
were performed using SPSS for Windows, version 6.0.1. P-
value of less than 0.05 (two-sided) was used to indicate a
significant difference.
To determine the contribution of the methodological var-
iation (CVanalyt) a representative sample was subdivided
into six samples. Each sample was then separately proc-
essed and analyzed. From these individual measurements,




Clinical chemistry, haematology and haemostatic labora-
tory values in the blood obtained from 29 healthy blood
donors were within the normal ranges. The average age
was 44 ± 12 years and did not significantly differ between
male and female (41 ± 10 vs. 46 ± 12 years, p > 0.05),
respectively.
During the perfusion through the rectangular chamber,
the platelet adhesion linearly increased with regard to the
exposition time at each tested shear rate. From 15 sec to 5
min of perfusion the platelet adhesion rates were 5-fold
(13 s-1), 6.8-fold (50 s-1) and 14.2-fold (1500 s-1), respec-
tively. After five minutes of perfusion at 13 s-1, 50 s-1 and
1500 s-1, averaged absolute fluorescence values were 6000
± 3796, 6715 ± 2461 and 55170 ± 22530, respectively (Fig
1, Fig 2).Thrombosis Journal 2006, 4:19 http://www.thrombosisjournal.com/content/4/1/19
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Taking into consideration individual and methodical var-
iation, our experimental system was validated. Analytical
variation (CVanalyt), tested through 6 repeated measure-
ments at 1500 s-1 and 50 s-1 (5 min of perfusion) of one
individual sample, indicated that our analytical variation
was 11% at 1500 s-1 and 7% at 50 s-1 respectively.
A specificity of binding of platelets to immobilized fibrin-
ogen was tested bi-directionally with two additional
experimental designs. In three experiments a blood was
additionally incubated with Abciximab (4 μg/ml for 10
min), c7E3 fragment, which showed a high affinity to
GPIIb-IIIa receptor. A perfusion (1500 s-1) of the preincu-
bated blood over fibrinogen-coated cover slips omits to
show significant platelet adherence (absolute fluores-
cence of stable adherent platelet: 168 U ± 35 U vs. 53000
U ± 19000 U at control experiments, p < 0.05). Similarly,
in experiments with perfusion of labelled platelets in
whole blood over BSA coated glass cover slips no signifi-
cant adherence was found. The relationship between
platelet adhesion and concentration of soluble plasma
fibrinogen was not found (p > 0.05). Additional experi-
ments, conducted with supplementation of soluble fibrin-
ogen (up to 9 g/L), omitted to show any difference with
regard to the untreated blood (data not present).
In each participant haemostatic laboratory parameters
were measured including antithrombin plasma activity
Microphotographs of platelets adhesion onto immobilized  fibrinogen after 1 minutes (A) and 5 minutes (B) of perfusion  at shear rate of 1500 s-1 Figure 2
Microphotographs of platelets adhesion onto immobilized 
fibrinogen after 1 minutes (A) and 5 minutes (B) of perfusion 
at shear rate of 1500 s-1.
Platelet adhesion onto immobilized fibrinogen under different  shear rate conditions with regard to the perfusion time (n =  29) Figure 1
Platelet adhesion onto immobilized fibrinogen under different 
shear rate conditions with regard to the perfusion time (n = 
29). 13 s-1 and 50 s-1 mimic venous flow and 1500 s-1 arterial 
flow. Platelet adhesion between 15 sec and five min of per-
fusion increased five-fold at shear rate of 13 s-1 and 14-fold at 
arterial shear rate of 1500 s-1. Per each subject 3 flow exper-
iments were conducted (13 s-1, 50 s-1 and 1500 s-1). Finally 87 
perfusion experiments were conducted. At each time point 
of perfusion (15 sec, 1 min and 5 min) a stack of 5 images was 
collected and analyzed.Thrombosis Journal 2006, 4:19 http://www.thrombosisjournal.com/content/4/1/19
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(Berichrom Anti-Thrombin III, Dade Behring, Marburg,
Germany) and AT mean value was 103 ± 9%, ranged
between 88% and 121%. Antithrombin plasma activity of
each participant was carefully evaluated and compared to
the platelet adhesion onto immobilized fibrinogen with
regard to the shear rate and time of perfusion. Table 1.
summarised relationship between plasma AT concentra-
tion and platelet adhesion at different shear rates. As it is
evident from the Table 1., a significant inverse correlation
between plasma AT concentration and platelet adhesion
onto immobilized fibrinogen was observed at shear rates
between 13 s-1 and 50 s-1 within one minute of perfusion
(r = -0.53 and r = -0.72, p < 0.01). Fig. 3 represents a rela-
tionship between platelet adhesion and plasma AT activ-
ity at low shear conditions (13 s-1, 15 sec of perfusion).
Except for AT, no significant relationship was detected
between platelet adhesion and other parameters at 13 s-1
and 50 s-1. Parameters of plasmatic hemostasis as well as
other biochemical parameters did not correlate with the
platelet adhesion. Spearman's correlation coefficients
between the platelet adhesion and examined variables
were not significant (p > 0.05). In experiments conducted
under arterial flow conditions (1500 s-1), no significant
relationship was found between the platelet adhesion and
plasma AT activity.
The results of platelet adhesion were stratified according
to plasma AT activity. Subjects with low and high AT
plasma activity (<95% and >105%) were further statisti-
cally evaluated in the light of results of platelet adhesion.
Fig 4. indicates that subjects with "low" plasma AT (92 ±
3%) have higher platelet adhesion at 13 s-1 and 50 s-1 com-
paring with subjects with "high" (117 ± 4%) AT plasma
concentration, 1786 ± 516 vs. 823 ± 331 and 1190 ± 125
vs. 347 ± 186, respectively (p < 0.05). In the next set of
experiments (n = 8) whole blood was aliquoted and one
aliquot was preincubated 30 minutes with AT. After blood
supplementation AT activity increased up to 280% com-
paring with 104 ± 9% in non-supplemented blood. The
platelet adhesion rate (13 s-1) between the first and fifth
minute after start of perfusion was 65% related to the
adhesion rate of a non-supplemented blood, 1.25 ± 0.17
vs. 1.95 ± 0,4 p = 0.008, respectively, as shown in the Fig
5. Opposite to our expectation application of heparin as
anticoagulant did not enhanced antiadhesion property of
AT. The platelet adhesion rate was 2.42 ± 1.7.
Discussion
The present study provides three major new results: firstly,
a platelet adhesion onto immobilized fibrinogen is signif-
icantly influenced through the plasma antithrombin
activity, secondly, this inhibitory AT effect was observed at
low shear stress conditions in the initial phase within one
minute, thirdly, a supraphysiological blood supplementa-
tion with AT significantly reduces platelet adhesion rate
between the first and fifth minutes.
AT is a member of serpin super family of proteinase inhib-
itors and plays a crucial role in the maintenance of normal
haemostasis. AT appeared at an early stage in the evolu-
tion of the vertebrate coagulation system. Andersen et al.
[21] reported a full length AT sequence from Atlantic
salmon fish, which appeared more than 450 million years
ago. AT is not only a strong inhibitor of thrombin but also
one effective inhibitor of factor IXa, Xa, XIa and XIIa.
Kondo et al [22] reported significant inhibition activity of
AT onto FVIIa. Described conventional and generally
accepted biological role of AT in haemostasis also
increased evidence about additional biological impor-
tance of AT [4,7-10,14].
Plot of plasma antithrombin activity and platelet adhesion  expressed as absolute fluorescence under low shear stress (n  = 29, shear rate 13 s-1, 15 sec of perfusion) Figure 3
Plot of plasma antithrombin activity and platelet adhesion 
expressed as absolute fluorescence under low shear stress (n 
= 29, shear rate 13 s-1, 15 sec of perfusion). Spearman's rank 
correlation coefficient was -0.53, p < 0.05.
Table 1: Relationship between platelet adhesion and plasma AT 
activity with regard to the perfusion time and shear rate
Perfusion time Shear rate, s-1
13 50 1500
15 second r = -0.53* R = -0.72* r = -0.11
1 minute r = -0.26 R = -0.07 r = -0.07
5 minute r = -0.34 R = -0.02 r = -0.05
*p < 0.05Thrombosis Journal 2006, 4:19 http://www.thrombosisjournal.com/content/4/1/19
Page 6 of 8
(page number not for citation purposes)
The present study provides the first experimental evidence
that the platelet adhesion onto immobilized fibrinogen is
suppressed by AT in physiological and supraphysiological
concentrations.
The first surprising result was significantly inversed corre-
lation (p < 0.01) between platelet adhesion onto immobi-
lized fibrinogen under low flow conditions (13 s-1 and 50
s-1) and plasma antithrombin activity. Observations that
platelet adhesion was significantly modulated through AT
(even AT plasma activity of all participants was in physio-
logical range, 88–121%) indicated a strong influence of
AT plasma activity onto platelet adhesion. A comparison
of platelet adhesion with belonging class (or subgroup) of
AT activity has confirmed a great significance AThave on
platelet adhesion under certain hemodynamic condi-
tions. The platelet adhesion activity in subgroup with a
high AT was 46% (average) lower, comparing to the sub-
group with a low AT activity (p = 0.001). This significant
influence of AT onto initial platelet adhesion (within first
minute) and subsequently on the growth of thrombus in
function of time was observed. The blood supplemented
with AT (final activity 280%) showed averaged 36% lower
platelet adhesion activity between the first and fifth
minute comparing with non-treated blood. This informa-
tion is of great importance since indicates AT influence on
the thrombus growth.
The observed AT modulation of platelet adhesion activity
is, according to our results, ligand, shear stress and time
dependent. AT suppression of platelet adhesion was
observed exclusively during the perfusion over immobi-
lized fibrinogen under low flow conditions (shear rate
between 13 s-1 and 50 s-1). Under arterial shear condition
(1500 s-1), no significant influence of AT was found. This
data indicated that specific reaction between platelets and
solid surface was simultaneously determined through the
shear stress. According to the generally accepted theory,
the platelet adhesion onto immobilized fibrinogen under
low flow conditions (up to 20 dyn/cm2, equivalent 500 s-
1) is exclusively modulated through GPIIb-IIIa (integrin
α2bβ3) as specific fibrinogen receptor [19,23]. Applica-
tion of Abciximab (specific inhibitor of GPIIb-IIIa) signif-
icantly reduces platelet adhesion onto fibrinogen and
simultaneously abolishes AT modulated platelet adhe-
sion. At the higher shear stress conditions, a stabile plate-
let adhesion onto immobilized fibrinogen is also, in time
and dose dependent manner, modulated through von
Anticoagulated blood (n = 8) was aliquoted and one aliquot  was supplemented with AT (final activity 280%) Figure 5
Anticoagulated blood (n = 8) was aliquoted and one aliquot 
was supplemented with AT (final activity 280%). Both aliq-
uots were further perfused through rectangular flow cham-
ber according to our experimental protocol. At low flow 
conditions (13 s-1) AT supplemented blood showed signifi-
cantly lower platelet adhesion rate (65% of adhesion com-
pared with non-supplemented blood, p < 0.05) between fifth 
and first minute.
Platelet adhesion under different shear rates was selected  according to the plasma antithromin activity of respected  samples Figure 4
Platelet adhesion under different shear rates was selected 
according to the plasma antithromin activity of respected 
samples. Low activity = plasma AT activity <95% (n = 7) and 
high activity = plasma AT activity >105% (n = 13). Statistically 
significant difference in platelet adhesion with regard to the 
low and high AT activity was observed at 13 s-1 and 50 s-1 (p 
< 0.05). Similar trend was observed under arterial flow con-
ditions but without statistical significance.Thrombosis Journal 2006, 4:19 http://www.thrombosisjournal.com/content/4/1/19
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Willebrand Factor (vWF) [19,24]. The source of vWF can
be plasma or platelet α-granules. We assume that AT also
could have a certain influence on the platelet adhesion
onto immobilized fibrinogen at high stress conditions but
this influence could be mimicked through the significant
vWF modulation.
Contrary to the fibrinogen, the platelet adhesion onto
immobilized collagen (data not present) showed no cor-
relation with plasma AT activity neither at venous nor
arterial flow condition. A supplementation with AT and
obtained supraphysiological AT plasma activity did not
influence a platelet adhesion and consecutive thrombus
growth onto immobilized collagen.
The absence of AT influence on the platelet adhesion onto
immobilized collagen and shear stress dependent AT
modulation of platelet adhesion onto immobilized
fibrinogen indicated that AT modulation was directed
through GPIIb-IIIa. Whether AT suppressed platelet adhe-
sion is influenced through HPA-1 polymorphism
(Leu33Pro polymorphism of integrin β3) could unfortu-
nately not be evaluated due to low incidence of HPA-1b1b
carrier in our study.
Mechanism by which AT suppresses a platelet adhesion is
unclear. A ligand-specific and shear stress dependent
modulation of platelet adhesion from blood already anti-
coagulated with PPACK (a strong thrombin inhibitor) as
well as experiments conducted with heparin could indi-
cated that AT suppressed platelet adhesion independent
from thrombin inactivation. To test this hypothesis four
experiments were conducted with heparin as anticoagu-
lant. It is well known that the inhibition of thrombin
through AT is by forming a 1:1 stoichiometric complex
between the two components via a reactive site (arginine)
– active centre (serine) interaction. This relatively slow
interaction in the presence of heparin is dramatically
accelerated [1,4]. Through the binding of heparin on the
AT and consecutive change of AT configuration, a capabil-
ity of AT to neutralise a clotting enzyme increased more
than 1000-folds. Opposite to our expectation in experi-
ments with heparinised blood, no significant influence of
supplemented AT onto platelet adhesion rate comparing
with the non-supplemented blood was not observed. This
observation could indicated that AT act was independent
from thrombin inactivation.
Uchiba et al. [7] indicated a promotional effect of AT onto
prostacycline cellular production and a release of consec-
utive reduction of the platelet activation. We assume that
this mechanism could not play significant role in our
experimental system since allotment of activated platelets
under low flow conditions was a very small and constant.
Larsson et al. [4] demonstrated a remarkable anti-ang-
iogenic effect of antithrombin in in-vivo animal model.
The author explained anti-angiogenic effect through the
observation that AT inhibits angiogenesis by impeding a
focal adhesion (endothelial cells) formation and focal
adhesion kinase activity. An incubation of the cells with
AT was found to reduce fibroblast growth factor 2 induced
focal adhesion kinase activity (FAK). FAK resides in the
focal contact and its activity is induced by integrin-med-
ited ligation of cells to the extra cellular matrix. FAK tyro-
sine phosphorylation is one of the early post-ligand-
binding events mediated by integrins, and relies essen-
tially on the functional β-subunit [25]. The exact mecha-
nism by which AT perturbs FAK activation, remains to be
determined. Being focused on an antiadhesion effect of
AT, Yamashiro et al. showed that AT inhibited leukocyte
rolling (tethering) along the retinal veins and that AT sub-
stitution significantly reduced P-selectin mRNA expres-
sion in the endothelial cells [26]. However, the
mechanism by which AT exerts its suppressing effects on
platelets adhesion is still unclear.
Conclusion
A vessel-wall injury and consecutive fibrinogen deposi-
tion provides ideal environment and the stimulus for the
initiation of clot formation [20,23,24]. An interaction
between immobilized fibrinogen and platelets does not
require previous platelet activation or conformational
changes in platelet GP IIb-IIIa and has been shown to
occur even in the presence of platelet inhibitors [23].
Since it has been widely believed that thrombus is formed
in the areas of low shear and stagnation (e.g. recirculation
zones) [18], our observations that AT significantly sup-
presses platelet adhesion onto immobilized fibrinogen
under low flow condition might have a potential thera-
peutic significance and have to be further evaluated.
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